CAR-T

What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China?

# What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China? #MultipleMyeloma #CAR_Therapy #MM #CART #RRMM #Hematology **Multiple Myeloma** (MM) is a malignant hematological disease that affects plasma cells. In recent years, various drugs and treatment methods, such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation, have significantly improved the Read More

October 24th,2024 Myeloma , CAR-T

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients!

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients! #Lymphoma #CAR_TCellTherapy #DLBCL#CancerHope #PatientStory Lymphoma has long been regarded as a “synonym for death,” with its high incidence and recurrence rates striking fear into many. However, with the rapid advancement of medical technology, a revolutionary new therapy is changing this Read More

October 23rd,2024 Lymphoma , CAR-T , patient story

At which stage of treatment is the best time to choose CAR-T therapy?

At which stage of treatment is the best time to choose CAR-T therapy? CAR-T therapy is often used as a last resort, but it should be introduced earlier for better outcomes. Early use, even as a frontline or 1.5-line treatment, could dramatically increase patient cure rates. Tumor cells are highly adaptable and intelligent, learning to Read More

October 22nd,2024 CAR-T

Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!

Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China! #FL #Lymphoma #FollicularLymphoma #CARTTherapy #CART #Patientstory **Patient Story – Oleg’s Cancer Journey:** Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease Read More

October 22nd,2024 CAR-T

Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma

Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma #CAR_Therapy #Glioblastoma #CancerResearch #InnovativeMedicine A Chinese medical team has recently made significant progress in t he field of CAR-T cell therapy, bringing new hope for the treatment of solid tumors such as glioblastoma (GBM). While CAR-T therapy has achieved great success in treating hematologic al malignancies, Read More

October 22nd,2024 Solid tumor , CAR-T

Why Are More and More International Patients Coming to China for CAR-T Cell Therapy?

Why Are More and More International Patients Coming to China for CAR-T Cell Therapy? #CARTtherapy #InternationalPatient #CART #Multiplemyeloma #lymphoma #leukemia In recent years, CAR-T cell therapy, as an innovative cancer treatment, has rapidly gained widespread attention globally. China, as a leading country in the CAR-T treatment field, has attracted an increasing number of patients from Europe and Read More

October 18th,2024 CAR-T

Global CAR-T Products on the Market and BCMA-Targeted CAR-T Products

Global CAR-T Products on the Market #CART #DLBCL #ALL #FL #MCL #MM #LBCL #Leukemia #Lymphoma #MultipleMyeloma Globally Approved BCMA-Targeted CAR-T Products – Multiple Myeloma #CART #MM #RRMM #MultipleMyeloma #Myeloma To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Read More

October 17th,2024 CAR-T

**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**

**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?** As an innovative immunotherapy, CAR-T therapy has gradually become available in China in recent years, attracting significant attention from patients. Although it is dubbed the “million-dollar therapy” due to its high cost, experts emphasize that CAR-T is not a conventional drug but a Read More

October 15th,2024 CAR-T

China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients

### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients   #MultipleMyeloma #CAR_TTherapy #BCMACART #CART Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant Read More

October 12th,2024 CAR-T

Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?

**Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?** #CAR_Therapy #CancerTreatment #MedicalInnovation #ChinaMedical In recent years, China has made rapid advancements in medical technology, particularly in the area of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This cutting-edge cancer treatment involves reprogramming a patient’s own T cells to recognize and attack cancer cells. Read More

October 11th,2024 CAR-T

Nature Headline! China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment  

🌟 **Nature Headline!** China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment #CAR_Therapy #CRISPR #AutoimmuneDisease #Immunotherapy #Nature #Autoimmune #IMNM #dcSSc #immunemediatednecrotizingmyopathy #cutaneoussystemicsclerosis 💪 Chinese medical scientists have made a major breakthrough in treating autoimmune diseases with revolutionary CAR-T therapy. This study, conducted by scientists from three Chinese universities, was published in the prestigious journal *Cell* on Read More

October 8th,2024 CAR-T

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.

The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies. 目前中美上市的11款CD19和BCMA CAR-T对血液瘤患者的意义 Expert： **Jing Pan** **Associate Chief Physician** **Department of Pediatric Hematology, Beijing Gaobo Hospital** **Professional Memberships:** – Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association – Youth Committee Member, Hematologic Oncology Professional Read More

October 2nd,2024 CAR-T